Treatment-resistant depression: your questions, answered

Depression is generally called treatment-resistant when a person has tried at least two different antidepressants, each at an adequate dose and for an adequate length of time, and neither produced meaningful relief. The term describes how the illness responds to medication, not how hard you have tried.

The common threshold is two adequate trials of different antidepressants that did not bring meaningful relief. Adequate means a real therapeutic dose taken for a long enough time, usually several weeks. Stopping early because of side effects is not the same as a full trial, and it is one of the first things a good clinician will review with you.

Established next-line options include esketamine (Spravato), a nasal spray that is FDA-approved for treatment-resistant depression; transcranial magnetic stimulation (TMS), which is FDA-cleared and drug-free; medication augmentation or combination strategies; evidence-based talk therapy; and, for severe cases, electroconvulsive therapy (ECT). The right choice depends on your history and is decided with a clinician.

Esketamine is derived from ketamine and is the specific form that is FDA-approved as a nasal spray for treatment-resistant depression, used alongside an oral antidepressant. It is given in a certified medical setting with a monitoring period afterward, usually about two hours. That supervision is a standard safety practice, not a warning sign.

TMS uses focused magnetic pulses to stimulate a region of the brain involved in mood, rather than a drug taken by mouth. It is done while you are awake, requires no anesthesia, and is delivered over a course of several weeks. Because it is drug-free, it can appeal to people who cannot tolerate medication side effects.

Timelines vary by treatment and by person. Oral antidepressants often take several weeks at an adequate dose. Some people notice changes from esketamine sooner than they typically would with pills, though this is not guaranteed. TMS benefits usually build gradually across a multi-week course. Improvement is generally a slope, not a switch.

Response means your symptoms have improved meaningfully, often defined as roughly a fifty percent reduction. Remission means your symptoms have dropped low enough that you would no longer be considered actively depressed. Response can feel like a real lift while some symptoms remain; remission is the fuller goal and can take longer or more than one treatment.

Both esketamine (Spravato) and TMS are FDA-approved or FDA-cleared for depression that has not responded to medication, and both are covered by many insurance plans when medical criteria are met. Coverage details depend on your specific plan, so it is worth confirming with the provider and your insurer before starting.

No. Not responding to the first medications is common and is information for your care team, not a verdict about you. Treatment-resistant depression is precisely the situation that next-line treatments were designed to address, and not responding to one option does not close the others.

Start with your own prescriber or a psychiatric clinic. Bring a list of the antidepressants you have tried, their doses, how long you took them, and what happened. Your doctor's involvement is often the single biggest factor in moving forward, so telling them plainly that the current plan is not working is a reasonable and important step.